Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 7/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23650062 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL7708120 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL30091055 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL6513309 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL30396368 | 0.94 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL27028364 | 0.94 | TYMP (0.56) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL7261560 | 0.94 | TYMP (0.56) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL27135325 | 0.94 | TYMP (0.56) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL8386141 | 0.93 | TYMP (0.67) | TYMPADORA1P2RY12 | |
| SCHEMBL917678 | 0.93 | TYMP (0.67) | TYMPADORA1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235362-A1 | RNA CAP ANALOGS AND METHODS OF USE | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |